drugset
Drugs / Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
last change Dec 2019 re-read 9 days ago

Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)

also known as BAY98-7106
Developed for
essential hypertension
Investigated by
Bayer

Trials 1

today NCT02047019 · Ph 3
2018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT02047019 Dec 2017 → Dec 2019 essential hypertension Bayer Withdrawn No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) ClinicalTrials.gov intervention name — accepted as the source's own label NCT02047019 ↗
Known as BAY98-7106 “Fixed Dose combination BAY98-7106 (nifedipine plus candesartan)” NCT02047019 ↗
Route Oral “Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 30/16 mg, tablet, orally, once daily” NCT02047019 ↗